xarelto
bayer ag - rivaroksabaani - arthroplasty, replacement; venous thromboembolism - antitromboottiset aineet - xarelto-valmistetta, samanaikaisesti asetyylisalisyylihapon (asa) yksin tai yhdessä asa plus klopidogreeli tai tiklopidiini, on tarkoitettu aterotromboottisten tapahtumien estämiseen aikuispotilaille, kun akuutti koronaarioireyhtymä (acs) kanssa sydänperäisten biomerkkiaineiden kohoamista. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. laskimotromboembolian (vte) ehkäisy aikuisilla potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban accord
accord healthcare s.l.u. - rivaroksabaani - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitromboottiset aineet - laskimotromboembolian (vte) ehkäisy aikuisilla potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 hemodynaamisesti epävakaa pe potilaat). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
revasc
canyon pharmaceuticals ltd. - desirudiinille - laskimotromboosi - antitromboottiset aineet - syvän laskimotromboosin ehkäisy potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen.
dexliq 4 mg/ml oraaliliuos
laboratoires ctrs - dexamethasone sodium phosphate - oraaliliuos - 4 mg/ml - deksametasoni
confidex 500 iu injektiokuiva-aine ja liuotin, liuosta varten
csl behring gmbh - human coagulation factor ix, human coagulation factor x, human coagulation factor ii, human coagulation factor iii, human protein c, human protein s - injektiokuiva-aine ja liuotin, liuosta varten - 500 iu - hyytymistekijät ix
confidex 1000 iu injektiokuiva-aine ja liuotin, liuosta varten
csl behring gmbh - human coagulation factor ix, human coagulation factor x, human coagulation factor ii, human coagulation factor iii, human protein c, human protein s - injektiokuiva-aine ja liuotin, liuosta varten - 1000 iu - hyytymistekijät ix
ghemaxan 10 000 iu (100 mg) / 1 ml injektioneste, liuos, esitäytetty ruisku
chemi s.p.a. - enoxaparin sodium - injektioneste, liuos, esitäytetty ruisku - 10 000 iu (100 mg) / 1 ml - enoksapariini
ghemaxan 15 000 iu (150 mg) / 1 ml injektioneste, liuos, esitäytetty ruisku
chemi s.p.a. - enoxaparin sodium - injektioneste, liuos, esitäytetty ruisku - 15 000 iu (150 mg) / 1 ml - enoksapariini
ghemaxan 2 000 iu (20 mg) / 0.2 ml injektioneste, liuos, esitäytetty ruisku
chemi s.p.a. - enoxaparin sodium - injektioneste, liuos, esitäytetty ruisku - 2 000 iu (20 mg) / 0.2 ml - enoksapariini
ghemaxan 4 000 iu (40 mg) / 0.4 ml injektioneste, liuos, esitäytetty ruisku
chemi s.p.a. - enoxaparin sodium - injektioneste, liuos, esitäytetty ruisku - 4 000 iu (40 mg) / 0.4 ml - enoksapariini